NORGINE B.V. ENTERS INTO EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENTS FOR THE COMMERCIALISATION OF PLENVU® IN A NUMBER OF COUNTRIES IN LATIN AMERICA, SOUTHERN AFRICA, CENTRAL AND EASTERN EUROPE
12 February 2020
Building partnerships is key to expanding our portfolio to achieve strong sustainable growth.
We want to win late stage partnering opportunities that will exploit our strengths and infrastructure in Europe, Australia and New Zealand.
We are committed to acquire specialised innovative products from companies in Europe, the US and elsewhere who have a complementary vision to improve patients’ lives. Through our agile and flexible organisation we have the ability to deploy a single opportunity across our entire network of affiliates or maximise opportunities locally.
We are focusing on specialist products which are:
Strong partnering track record
Many ways to partner: licensing, acquisition, joint venture, flexible deal structure
One Norgine: over 1,300 people, a direct presence in 12 European countries, as well as Australia and New Zealand
Specialist therapy areas: gastroenterology, hepatology, cancer and supportive care
€419 million net product sales in 2019
One Norgine approach – we think globally but act locally.
We license in or acquire products in late stage development or already approved such that either -
we own the asset outright and control all future development
we share responsibility for future development in collaboration with the licensor
We make our products such as MOVICOL®, MOVIPREP® and PLENVU®, available to patients in territories where we do not have our own sales force by finding suitable partners and utilising their local knowledge and expertise
As a private company we are able to be creative and flexible in the structure of deals